Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI
Status:
Unknown status
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Prolonging infusions may decrease myocardial damage associated with bivalirudin use during
primary PCI. The investigators hypothesized that continuing the bivalirudin infusion
commenced during the procedure at the PCI recommended dose for 4 hours would prevent
myocardial damage.